Literature DB >> 7520169

High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.

S J Raphael1, G McKeown-Eyssen, S L Asa.   

Abstract

The pathologic diagnosis of thyroid tumors is often difficult and subjective. Immunohistochemical markers including high molecular weight cytokeratin (HMW-CK), cytokeratin-19 (CK-19) and epithelial membrane antigen have been suggested to be helpful in the distinction of various types of thyroid neoplasia. We collected frozen and/or paraffin-embedded tissues from a total of 116 surgically resected thyroids including 31 nodular hyperplasias, 18 follicular adenomas, 48 papillary carcinomas and 19 follicular carcinomas, stained them for HMW-CK, CK-19 and epithelial membrane antigen, and graded the results on a scale from 0 to 3+. Although little staining for HMW-CK was seen in paraffin-embedded tissues, different results were obtained when both HMW-CK and CK-19 were tested on frozen tissues. In papillary carcinomas, including the follicular variant of papillary carcinoma, diffuse positivity for these antigens was seen immunohistochemically, and these antigens significantly distinguished papillary carcinomas from follicular neoplasms and nodular hyperplasias. Focal staining for epithelial membrane antigen was found in all pathological processes; thus this marker was not useful. We conclude that HMW-CK and CK-19 are useful in the distinction of papillary carcinomas from follicular adenomas, follicular carcinomas, and nodular hyperplasias when applied to frozen tissues. We recommend that samples of thyroid follicular nodules be frozen, and retrieved if necessary to aid in the differential diagnosis of these tumors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520169

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  15 in total

Review 1.  The meanings of markers: ancillary techniques in diagnosis of thyroid neoplasia.

Authors:  Simon J Raphael
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

Review 2.  Best practice in thyroid pathology.

Authors:  C E Anderson; K M McLaren
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

3.  ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy.

Authors:  Electron Kebebew; Miao Peng; Emily Reiff; Quan-Yang Duh; Orlo H Clark; Alex McMillan
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

4.  Pattern of expression of intermediate cytokeratin filaments in the thyroid gland: an immunohistochemical study of simple and stratified epithelial-type cytokeratins.

Authors:  E Fonseca; J M Nesland; J Höie; M Sobrinho-Simões
Journal:  Virchows Arch       Date:  1997-03       Impact factor: 4.064

5.  Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.

Authors:  Nobuki Nakamura; Lori A Erickson; Long Jin; Sabine Kajita; Heyu Zhang; Xiang Qian; Kandelaria Rumilla; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

6.  Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Roberta DePompa; Enrico Saggiorato; Armando Bartolazzi; Fabio Orlandi; Mauro Papotti
Journal:  Virchows Arch       Date:  2004-07-14       Impact factor: 4.064

7.  Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.

Authors:  Magdalena Slosar; Poonam Vohra; Manju Prasad; Andrew Fischer; Robert Quinlan; Ashraf Khan
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

8.  RET/PTC and CK19 expression in papillary thyroid carcinoma and its clinicopathologic correlation.

Authors:  Eunah Shin; Woung Youn Chung; Woo Ick Yang; Cheong Soo Park; Soon Won Hong
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

9.  Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid.

Authors:  Suna Erkiliç; Abdullah Aydin; N Emrah Koçer
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

10.  Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1.

Authors:  Mary B Casey; Christine M Lohse; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.